Equity The musician-turned-biotech-founder waiting to fundraise
11 snips
Apr 15, 2026 
Aloe Blacc, Grammy-nominated singer-songwriter turned biotech entrepreneur, is bootstrapping a cancer drug platform while learning the rules of science funding. He discusses shifting from writing checks to building, using a molecule-discovery platform to speed drug development, and watching AI reshape both biotech and music — plus why artists still matter in the age of AI.
AI Snips
Chapters
Transcript
Episode notes
University Platform Expands What Drugs Can Target
- Aloe Blacc moved from philanthropy to operator because biotech needs administrative structure and commercialization, not just checks.
- He partnered with Dr. Gomika Udugamasoria at University of Houston whose molecule-discovery platform binds diverse structures, widening therapeutic targets beyond proteins.
COVID Sparked Building A Company Not Just Donating
- COVID prompted Aloe Blacc to fund research after breakthrough infection despite vaccination, revealing philanthropy alone can't push university IP through trials.
- He formed Major Inc. to license university IP and run external research the university lacked facilities to do.
Biotech Has Multiple Sequential Kill Points
- Biotech faces layered headwinds: bench science failures, regulatory hurdles, clinical trial uncertainty, and fast-follow competition.
- Aloe emphasizes that even minor market shifts can scare investors away despite solid science.